Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2750048 | 0.97 | KMT2A (0.59) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2750239 | 0.93 | KMT2A (0.55) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2749560 | 0.93 | KMT2A (0.55) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2750955 | 0.92 | NPC1 (0.55) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2751881 | 0.91 | KMT2A (0.49) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2748923 | 0.91 | KMT2A (0.50) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2750179 | 0.91 | ALDH1A1 (0.56) | KMT2AATMCYP1A2CYP2C19LMNA | |
| SCHEMBL2749989 | 0.91 | KMT2A (0.52) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2750140 | 0.90 | KMT2A (0.52) | KMT2AATMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2750314 | 0.90 | HPGD (0.49) | KMT2AATMNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406226-B1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-09-16 | — | — | EP | claimed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | claimed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | claimed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | claimed |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | US | claimed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | KMT2A 254/4885ATM 4336/4885NPC1 1123/4885 |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | KMT2A 422/4885ATM 4224/4885NPC1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.